ACI 35

Drug Profile

ACI 35

Alternative Names: Anti-pTau vaccine - AC Immune

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator AC Immune
  • Developer AC Immune; Janssen Pharmaceuticals
  • Class Alzheimer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 12 Jan 2015 Janssen Pharmaceuticals acquires worldwide exclusive licence to ACI 35 from AC Immune
  • 14 Jan 2014 Biomarkers information updated
  • 09 Jan 2014 Phase-I clinical trials in Alzheimer's disease (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top